NRG1 Fusion clinical trials at UC Irvine

1 in progress, 0 open to eligible people

Showing trials for

  • Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

    Sorry, in progress, not accepting new patients

    This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion (eNRGy)

    Irvine, California and other locations

Last updated: